bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Marcy-l'Étoile, FR
Size (employees)
9,806 (est)+5%
bioMerieux was founded in 1963 and is headquartered in Marcy-l'Étoile, FR
Report incorrect company information

Key People/Management at bioMerieux

Alexandre Mérieux

Alexandre Mérieux

Chairman and CEO
Michel Baguenault

Michel Baguenault

General Secretary, Corporate VP, Human Resources and Communications
Nicolas Cartier

Nicolas Cartier

Corporate VP, Industry Unit
Pierre Charbonnier

Pierre Charbonnier

Corporate VP, Manufacturing & Supply Chain
Claire Giraut

Claire Giraut

Corporate VP and Chief Financial Officer
François Lacoste

François Lacoste

Corporate VP, Clinical Unit
Mark Miller

Mark Miller

Corporate VP, Chief Medical Officer
Yasha Mitrotti

Yasha Mitrotti

Corporate VP, Europe, Middle East, Africa Region & Global Commercial Performance
Alain Pluquet

Alain Pluquet

Corporate VP, Chief Data Officer
Randy Rasmussen

Randy Rasmussen

Corporate VP, Molecular Biology
Kirk Ririe

Kirk Ririe

Corporate VP, Chief Innovation Officer
Stefan Willemsen

Stefan Willemsen

Corporate VP, Americas Region, Group Chief Legal Officer

bioMerieux Office Locations

bioMerieux has an office in Marcy-l'Étoile
Marcy-l'Étoile, FR (HQ)
376 Chemin de l'Orme
Show all (1)
Report incorrect company information

bioMerieux Financials and Metrics

bioMerieux Financials

bioMerieux's revenue was reported to be €2.10 b in FY, 2016 which is a 7.1% increase from the previous period.

Revenue (FY, 2016)

2.1 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

1.1 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

179.2 m

EBIT (FY, 2016)

282.5 m

Market capitalization (2-Oct-2017)

8 b

Closing share price (2-Oct-2017)


Cash (2-Mar-2018)

178.6 m


8.2 b
bioMerieux's current market capitalization is €8 b.
EURFY, 2014FY, 2015FY, 2016


1.7 b2 b2.1 b

Revenue growth, %


Cost of goods sold

853.9 m975.4 m1 b

Gross profit

844.5 m989.2 m1.1 b
EURFY, 2014FY, 2015FY, 2016


119.7 m147.1 m178.6 m

Accounts Receivable

449.3 m445.1 m465.8 m


299.2 m355.8 m404.4 m

Current Assets

991.4 m1.1 b1.2 b
EURFY, 2014FY, 2015FY, 2016

Net Income

135.5 m110.3 m179.2 m

Cash From Operating Activities

298.3 m310 m335.6 m

Purchases of PP&E

(158.1 m)(208.2 m)(233 m)

Cash From Investing Activities

(502.7 m)(208 m)(257.2 m)
EURY, 2016


29.2 x


24.6 x


224.3 k


0.3 x


0.1 x

Financial Leverage

1.9 x
Show all financial metrics

bioMerieux Operating Metrics

FY, 2015FY, 2016





Patents and Patent Applications

581 529
Show all operating metrics
Report incorrect company information

bioMerieux News and Updates

Infection Surveillance Solutions Market Estimated to Exhibit 14.4% CAGR during 2017-2025

Global infection surveillance solution market to register a staggering 14.04% CAGR during the forecast- 2017 to 2025. The US$ 316.67 Mn market is likely to surpass US$ 900 Mn in revenues by 2025-end. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information